Accumulation of effective immunity against SARS-CoV2 infection and non-SARS human coronaviruses (hCoVs) is likely possible in patients with hematologic malignancies who have undergone a hematopoietic stem cell transplantation (HSCT).
These findings from a study of patients with hematologic malignancies versus healthy volunteers were presented at the 2021 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR.
“Our findings have implications for the rational use of the upcoming vaccines and for development of broader cross-reactive anti-hCoV T-cell–based immunotherapy approaches for these highly vulnerable group of patients,” the investigators wrote in their poster presentation.
The coronavirus disease 2019 (COVID-19) has affected individuals with comorbidities—including those with cancer, in particular—and causes severe respiratory infections among immunocompromised…
